Nordic Life Science 1
BUSINE S S The partnership with Acelyrin aims to
develop and commercialize izokibep, while the purpose of the collaboration with Lokon Pharma is to combine oncolytic viruses with Affibody molecules. I ZOKIBEP IS A BISPECIFIC MOLECULE targeting interleukin-17A for multiple autoimmune diseases. In the agreement with Acelyrin, Affibody will receive a 25 million USD upfront payment and is eligible to receive up to 280 million USD in additional regulatory and sales milestones, plus high single-digit to low double-digit royalties on sales. Acelyrin has obtained worldwide rights to izokibep, except development and commercialization rights already granted to Affibody’s partner Inmagene in selected Asian countries. Additionally, Affibody is retaining commercialization rights in the Nordic countries. Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. “The small size of, and potential for, high affinity makes Affibody molecules highly interesting tools for a novel treatment regime with adenovirus platforms,” says Fredrik Frejd, CSO, Affibody.